BeyondSpring (BYSI) Asset Utilization Ratio (2020 - 2026)
BeyondSpring (BYSI) posted Asset Utilization Ratio of 0.09 for Q1 2026, up 24.98% sequentially from 0.07 in Q4 2025, and up 61.07% YoY from 0.06 in Q1 2025.
BeyondSpring (BYSI) Asset Utilization Ratio (2020 - 2026) Analysis & Trends
BeyondSpring has reported Asset Utilization Ratio for 4 years, with the latest figure at 0.09 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 61.07% year-over-year to 0.09 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.09 (up 61.07% YoY) and the FY2022 annual result came in at 0.02, up 55.38% from the prior year.
- Asset Utilization Ratio grew to 0.09 in Q1 2026 per BYSI's latest filing, from 0.07 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.09 in Q1 2026 and troughed at 0.06 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | 0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.12 |
| Mar 31, 2026 | 0.09 |
| Dec 31, 2025 | 0.07 |
| Sep 30, 2025 | 0.07 |
| Jun 30, 2025 | 0.06 |
| Mar 31, 2025 | 0.06 |
| Dec 31, 2021 | 0.02 |
| Sep 30, 2021 | 0.01 |
| Jun 30, 2021 | 0.01 |
| Mar 31, 2021 | 0.00 |
| Dec 31, 2020 | 0.00 |